This was presumably the first update bearing the imprimatur of the new CEO. Unfortunately not much new but only a week in the top job, hopefully he is a under-promise, over-deliver kind of guy! They have acknowledged that the market volume for testosterone is decreasing and crossing their fingers ex-US sales and FEx will make up the difference. Not much joy there while we wait for FDA to make up their minds on actions to arise from the Advisory Committee findings. One slide which I haven't seen before was the "FACILITIES, PROCESS AND CAPABILITIES", perhaps leveraging this facility for future product development? All in all there is no disguising the fact that there is a huge gap between the marketed products and those in development so this company will be a one-trick pony for a while yet it seems. Still, the dividend isn't bad.
ACR Price at posting:
$1.06 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)